u/viktor_laurent

Not convinced.

baseline_drifter is right about the escalation being the variable. It explains most of the difficult reports here.

That figure is a private price at one pharmacy, not a national one.

Not convinced. You are attributing a week of food noise to the glucagon arm when the escalation rate alone would explain it.

Cosigning on asking the pharmacy to check the wholesaler. It converts speculation into a fact in one phone call.

Yes. Lean mass change during weight loss is expected; the useful question is the proportion, not whether it happens.

Push back: PCOS as a diagnosis and insulin resistance as a finding are not interchangeable, and the thread is using them as one.

Appetite is the proximal effect and weight is the lagging integrated outcome, which is why watching appetite gives you an earlier and more honest signal.

Yes — the rodent literature is real and it is rodent literature. The gap to a human claim is enormous and it gets crossed in one sentence here.

daily dosing, not weekly, so the exposure profile is different

This. New Zealand has its own regulator and its own funding decisions and the answers genuinely differ.

the trials were not designed to answer most of the questions asked here

Has this been raised with whoever prescribes?

Adding the one thing nobody warns about — fertility can change, and quickly.

Submissions older than a year are archived: readable, linkable, and closed to new comments. That keeps a three-year-old thread from being reopened with a reply nobody will see in context.

The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.

Reduced appetite makes hitting a protein target a logistics problem rather than a motivation problem, which is why the practical advice here is about timing and food choice rather than willpower.

the energy-expenditure story is mechanistically interesting and clinically unproven

What would the new rule do to the vendor evidence standard?

Was there identity confirmation, or only a purity figure?

Right — strength retention is a free proxy and it tracks better than most people expect.

Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.

That is body weight change, not fat mass.

clara_weiss is right about the escalation being the variable. It explains most of the difficult reports here.

log what you did, not what you meant to do

Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.

Not convinced. You are attributing a week of injection-site soreness to the glucagon arm when the escalation rate alone would explain it.

Are you tracking heart rate at all?

Rang three pharmacies for a private price and got three different numbers, all in the same city.

Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.

a log with no dates is a story

Agreed that the vocabulary here is imprecise and it causes people to answer different questions to the ones asked.

This. Modmail first is not bureaucracy; it stops individual cases turning into a public pile-on.

do not compare your composition to a trial average

pentadecapeptide, fifteen residues, and the sequence is public

the appetite effect makes eating enough protein a logistics problem

Not convinced by the proposal as worded. It would remove the specific thing that makes the vendor board usable.

protein intake gets harder exactly when appetite drops

That reads as advice to stop, which is not something anyone here should be offering.

Cosigning that the papers are more modest than the summaries of them. That is true across this whole site and especially here.

Are you comparing against phase 3 numbers for something else? They are not comparable.